Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

The Chemicals industry as a whole closed the day down 1.4% versus the S&P 500, which was down 0.3%. Laggards within the Chemicals industry included

Metabolix

(

MBLX

), down 7.2%,

Delta Technology Holdings

(

DELT

), down 14.1%,

NL Industries

(

NL

), down 10.6%,

Marrone Bio Innovations

(

MBII

), down 3.0% and

Valhi

(

VHI

), down 10.1%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Marrone Bio Innovations

(

MBII

) is one of the companies that pushed the Chemicals industry lower today. Marrone Bio Innovations was down $0.06 (3.0%) to $1.97 on light volume. Throughout the day, 32,524 shares of Marrone Bio Innovations exchanged hands as compared to its average daily volume of 143,800 shares. The stock ranged in price between $1.87-$2.02 after having opened the day at $2.02 as compared to the previous trading day's close of $2.03.

Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products for the crop protection, water treatment, and other target markets in the United States and internationally. Marrone Bio Innovations has a market cap of $45.9 million and is part of the basic materials sector. Shares are down 43.8% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Marrone Bio Innovations a buy, no analysts rate it a sell, and 2 rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates

Marrone Bio Innovations

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

Highlights from TheStreet Ratings analysis on MBII go as follows:

  • MARRONE BIO INNOVTIONS has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. For the next year, the market is expecting a contraction of 86.2% in earnings (-$1.75 versus -$0.94).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Chemicals industry. The net income has significantly decreased by 533.6% when compared to the same quarter one year ago, falling from -$1.64 million to -$10.39 million.
  • MBII, with its decline in revenue, slightly underperformed the industry average of 11.5%. Since the same quarter one year prior, revenues fell by 19.4%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • Compared to other companies in the Chemicals industry and the overall market, MARRONE BIO INNOVTIONS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 80.76%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 455.55% compared to the year-earlier quarter.

You can view the full analysis from the report here:

Marrone Bio Innovations Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close,

NL Industries

(

NL

) was down $0.71 (10.6%) to $6.02 on heavy volume. Throughout the day, 46,330 shares of NL Industries exchanged hands as compared to its average daily volume of 23,500 shares. The stock ranged in price between $5.78-$6.76 after having opened the day at $6.70 as compared to the previous trading day's close of $6.73.

NL Industries, Inc., through its subsidiary, CompX International Inc., operates in the component products industry in the United States and internationally. NL Industries has a market cap of $334.0 million and is part of the basic materials sector. Shares are down 21.7% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate NL Industries a buy, 1 analyst rates it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates

NL Industries

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on NL go as follows:

  • The revenue growth came in higher than the industry average of 3.6%. Since the same quarter one year prior, revenues slightly increased by 8.2%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • NL has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.42, which clearly demonstrates the ability to cover short-term cash needs.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Commercial Services & Supplies industry and the overall market on the basis of return on equity, NL INDUSTRIES has underperformed in comparison with the industry average, but has exceeded that of the S&P 500.
  • The gross profit margin for NL INDUSTRIES is currently lower than what is desirable, coming in at 33.95%. Regardless of NL's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, NL's net profit margin of 36.00% significantly outperformed against the industry.
  • NL has underperformed the S&P 500 Index, declining 22.58% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

You can view the full analysis from the report here:

NL Industries Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Metabolix

(

MBLX

) was another company that pushed the Chemicals industry lower today. Metabolix was down $0.25 (7.2%) to $3.23 on light volume. Throughout the day, 1,409 shares of Metabolix exchanged hands as compared to its average daily volume of 21,400 shares. The stock ranged in price between $3.23-$3.35 after having opened the day at $3.33 as compared to the previous trading day's close of $3.48.

Metabolix, Inc., an advanced biomaterials company, focuses on delivering sustainable solutions to the plastics industry. The company develops and commercializes technologies for the production of polymers and chemicals in microbes and plants. Metabolix has a market cap of $75.0 million and is part of the basic materials sector. Shares are up 40.9% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Metabolix a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Metabolix

as a

sell

. The area that we feel has been the company's primary weakness has been its disappointing return on equity.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Highlights from TheStreet Ratings analysis on MBLX go as follows:

  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Chemicals industry and the overall market, METABOLIX INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has increased to -$6.66 million or 25.69% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -16.51%.
  • MBLX has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.41, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to where it was a year ago today, the stock is now trading at a higher level, and has traded in line with the S&P 500. Turning our attention to the future direction of the stock, we do not believe this stock offers ample reward opportunity to compensate for the risks, despite the fact that it rose over the past year.
  • METABOLIX INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, METABOLIX INC continued to lose money by earning -$3.48 versus -$5.34 in the prior year. This year, the market expects an improvement in earnings (-$0.96 versus -$3.48).

You can view the full analysis from the report here:

Metabolix Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.